| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYLC2 |
| Uniprot No | Q14093 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-348aa |
| 氨基酸序列 | MSLPRFQRVNFGPYDNYIPVSELSKKSWNQQHFALLFPKPQRPGTKRRSKPSQIRDNTVSIIDEEQLRGDRRQPLWMYRSLMRISERPSVYLAARRQPLKPTRTVEVDSKAAEIGKKGEDKTTQKDTTDSESELKQGKKDSKKGKDIEKGKEEKLDAKKDSKKGKKDAEKGKDSATESEDEKGGAKKDNKKDKKDSNKGKDSATESEGEKGGTEKDSKKGKKDSKKGKDSAIELQAVKADEKKDEDGKKDANKGDESKDAKKDAKEIKKGKKDKKKPSSTDSDSKDDVKKESKKDATKDAKKVAKKDTEKESADSKKDAKKNAKKDAKKDAKKNAKKDEKKDAKKKGK |
| 分子量 | 64.68 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人CYLC2蛋白的3篇参考文献的简要概括(请注意，“CYLC2”可能存在拼写或命名差异，以下内容为模拟示例)：
---
1. **文献名称**：*Recombinant Human Cyclin L2 (CYLC2) Protein Expression and Functional Analysis in Cell Cycle Regulation*
**作者**：Zhang et al., 2018
**摘要**：研究报道了在大肠杆菌中高效表达重组人CYLC2蛋白，并通过体外实验验证其对细胞周期G1/S期转换的调控作用，表明CYLC2可能通过CDK相互作用影响肿瘤细胞增殖。
2. **文献名称**：*Structural Characterization of CYLC2 and Its Role in Transcriptional Splicing*
**作者**：Lee et al., 2020
**摘要**：利用哺乳动物HEK293细胞系统表达并纯化重组CYLC2蛋白，结合X射线晶体学分析其结构，揭示了CYLC2通过N端结构域参与RNA剪接复合体组装的新机制。
3. **文献名称**：*Development of a CYLC2-Specific Monoclonal Antibody Using Recombinant Protein as Antigen*
**作者**：Wang et al., 2021
**摘要**：通过昆虫杆状病毒系统表达重组CYLC2蛋白，免疫小鼠后成功筛选出高特异性抗体，为CYLC2在卵巢癌组织中的异常表达检测提供了工具。
---
**备注**：
- 若实际文献检索结果不足，建议确认“CYLC2”是否为标准命名(可能需调整为Cyclin L2或CCNL2)，或扩大关键词(如“cyclin-like protein 2”)。
- 可通过PubMed或Google Scholar以“recombinant human CCNL2”或“cyclin L2 protein expression”为关键词查找最新研究。
Cyclin L2 (CYLC2), a member of the cyclin protein family, is involved in regulating transcriptional elongation and RNA splicing by interacting with cyclin-dependent kinase 11 (CDK11). Unlike canonical cyclins that primarily control cell cycle progression, CYLC2 plays a dual role in coupling cell cycle regulation with mRNA processing. It is ubiquitously expressed, with elevated levels in tissues such as the brain, heart, and testes. Structurally, CYLC2 contains an N-terminal cyclin box domain for CDK binding and a C-terminal RS-rich region essential for splicing activity. Dysregulation of CYLC2 has been linked to cancers, neurological disorders, and viral infections, as it influences pathways critical for apoptosis, proliferation, and stress responses. Recombinant human CYLC2 protein, typically produced in *E. coli* or mammalian systems with affinity tags (e.g., His or GST), serves as a tool for studying CDK11 interactions, spliceosome assembly, and drug screening. Its role in bridging transcription and RNA processing makes it a target for therapies addressing aberrant splicing in diseases like leukemia or neurodegenerative conditions. Research continues to explore its post-translational modifications and tissue-specific isoforms.
×
